Method and compositions for enhancing the safety of orally administered magnesium alpha-lipoate

A method of enhancing the safety of and reducing the adverse effects caused by a pharmaceutical composition comprising magnesium alpha-lipoate when administered to a warm-blooded animal, comprising administering to said warm-blooded animal in a coordinated manner a first dosage of magnesium alpha-lipoate and a second dosage of D-biotin, wherein said first dosage comprises about 0.1 to about 100 milligrams magnesium, on an elemental basis, in the form of magnesium alpha-lipoate and said second dosage comprises about 0.01 to about 50 milligrams D-biotin.

An oral composition useful for enhancing the safety of and reducing the adverse effects caused by magnesium alpha-lipoate following administration to a warm-blood animal, comprising a unit dosage or serving of from about 5 milligrams to about 100 milligrams magnesium, on an elemental basis, in the form of magnesium alpha-lipoate and from about 0.01 milligrams to about 50 milligrams D-biotin.

A method of enhancing the safety of and reducing the adverse effects caused by magnesium R-(+)-alpha-lipoate following administration to a human, comprising administering to said human a first dosage of magnesium R-(+)-alpha-lipoate and a second dosage of D-biotin, wherein said first dosage comprises about 0.1 to about 100 milligrams magnesium, on an elemental basis, in the form of magnesium R-(+)-alpha-lipoate and said second dosage comprises about 0.01 to about 50 milligrams D-biotin.